Making the Path to Approval More Predictable Through Integrated Regulatory Submission Readiness 
6 min read

For pharmaceutical and biopharmaceutical companies, the journey from drug development to Regulatory approval involves a series of interconnected decisions that shape Regulatory submission readiness well before the final filing milestone. 

The Regulatory pathway selected during development influences the evidence that needs to be generated. Manufacturing and quality decisions shape the scientific content of the dossier. Submission requirements determine how that information must be structured, validated and presented. Once an application enters Regulatory review, the ability to respond to Health Authority questions depends on how well these activities have been coordinated.  

Each of these decisions has implications for the next stage.  

In our view, a more predictable path to approval begins with integrated Regulatory readiness, in which strategy, scientific documentation, submission execution, and review preparedness are planned as connected activities.  

Predictability does not imply certainty in Regulatory outcomes or review timelines. It comes from having greater clarity on requirements, identifying dependencies early, anticipating potential gaps and maintaining the ability to respond as Regulatory expectations and development programmes evolve.  

Regulatory strategy sets the direction for everything that follows  

The decisions made during Regulatory pathway planning can have lasting implications for a product's development and submission journey.  

Identifying the appropriate Regulatory route, evaluating country-specific requirements, assessing available special or expedited programmes and planning Health Authority interactions are important considerations during early development.  

For companies targeting registration in multiple markets, the complexity increases. Although global harmonisation has established common principles, Regulatory expectations can still differ across agencies, particularly regarding clinical evidence, product-specific requirements, and regional submission procedures.  

The ICH E17 guideline on multi-regional clinical trials, for example, emphasises the importance of considering regional factors during clinical trial planning to support the acceptability of evidence across Regulatory jurisdictions .  

This makes early Regulatory assessment particularly valuable. Understanding the expectations of priority markets can help sponsors identify potential gaps while there is still an opportunity to address them within the development plan. However, Regulatory strategy also needs to remain responsive. As clinical data emerge, manufacturing processes mature, or target markets change, assumptions made earlier in development may need to be revisited.  

The value of Regulatory strategy lies in establishing a clear direction while maintaining the flexibility to respond to evolving scientific and Regulatory requirements.  

Submission readiness begins with the scientific integrity of the dossier  

As development progresses, the focus increasingly shifts toward bringing together clinical, nonclinical, manufacturing, and quality information for a Regulatory submission.  

The Common Technical Document (CTD) provides a harmonised structure for presenting this information. However, the quality of a submission depends on more than the completeness of individual documents. The scientific rationale must remain consistent across dossier sections. For example, manufacturing process information needs to align with the control strategy and supporting quality data. Clinical summaries should accurately reflect the underlying study results, with relevant evidence supporting nonclinical conclusions, and the content should align with recent country-specific requirements.  

Changes introduced during development may also have implications across multiple documents and functional areas.  

The ongoing ICH M4Q(R2) revision reinforces the importance of how quality information is restructured and presented to support Regulatory assessment and lifecycle management. As of October 2026, the revision remains at Step 2b and has not reached final implementation.  

For Regulatory teams, these updated requirements reinforce the value of structured document management, scientific consistency and cross-functional review. A well-coordinated dossier development process allows Regulatory Affairs CMC, Clinical, Non-Clinical, labelling/Artwork, safety, and other Quality teams to identify information gaps, mitigate inconsistencies, and maintain alignment as the application progresses.  

Submission readiness becomes stronger when the dossier is developed as a coherent scientific package, with clear ownership of the supporting evidence and its Regulatory context.  

Submission execution connects scientific readiness with Regulatory requirements.  

Once the scientific content is prepared, successful filing execution depends on another set of coordinated activities.  

Submission planning, documents gap analysis, authoring, finalisation, publishing, technical validation and dispatch must align with the requirements of the relevant Health Authority. These activities are especially important for organisations managing submissions across multiple regions, application types and Regulatory standards.  

The continuing evolution of eCTD provides a relevant example.  

In September 2026, the US FDA updated its eCTD v4.0 regional implementation guide and controlled vocabulary package, reflecting ongoing changes in electronic submission standards [3].  

For Regulatory operations teams, developments of this nature require attention to the technical specifications and validation criteria applicable to each submission. They also have implications for document lifecycle management, submission workflows, internal quality controls and coordination between Regulatory and publishing teams.  

The requirements for an IND, CTA, NDA, ANDA, or BLA can differ depending on the application type, product, and Regulatory jurisdiction. Planning these submissions effectively requires both scientific understanding and operational discipline. A connected submission process helps ensure that changes to Regulatory content are reflected in publishing plans, that applicable technical requirements are addressed and that responsibilities remain clear throughout execution.  

When Regulatory strategy, gap analysis of documents/data, dossier preparation and submission operations remain aligned, teams are better positioned to manage filing requirements and avoid preventable last-minute rework.  

Review readiness is an extension of submission readiness.  

Regulatory engagement continues after a dossier has been submitted. During review, Health Authorities may seek clarification or additional information regarding clinical findings, CMC documentation, product development principles, product quality, labelling, GMP or other aspects of the application. Responding to these questions can require coordinated input from multiple scientific and Regulatory functions.  

The FDA's public Complete Response Letter resources provide further visibility into the range of deficiencies that can prevent applications from being approved in their current form [4]. This highlights why Regulatory preparedness needs to extend into the review stage. For example, a Health Authority question concerning the justification for a manufacturing control strategy, Stability...may require input from CMC specialists, manufacturing teams, Quality, and Regulatory Affairs experts.  

The response needs to be scientifically supported, consistent with the supporting data generated for the product and prepared in accordance with the applicable Regulatory process.  

Organisations that establish clear response ownership, support data access, escalation procedures, and document controls during submission preparation may be better equipped to manage such interactions. Where appropriate, proactive engagement with the Health Authority can also help clarify expectations and inform Regulatory decisions during development and review.  

The ability to navigate Regulatory review is strengthened by the knowledge, documentation and cross-functional coordination established throughout the preceding stages.  

Connecting Regulatory decisions across the product journey  

The importance of integrated readiness becomes particularly clear when a change in one domain/section has consequences elsewhere. Consider a manufacturing process modification introduced as a product approaches its planned submission date.  

The change may require updated CMC documentation, additional scientific justification, revisions to dossier summaries and adjustments to submission planning. Depending on its significance and timing, the Regulatory team may also need to evaluate the potential implications for interactions with the Health Authority.  

Each activity may sit with a different functional team, but the decisions are interdependent.  

The same principle applies when a company expands its submission strategy into additional markets, receives new clinical evidence or encounters questions during Regulatory review. Managing these situations effectively requires visibility across the Regulatory journey and a shared understanding of how individual decisions affect the overall submission plan.  

For sponsors, integrated Regulatory readiness can be supported through several practical disciplines:  

  • Early identification of Regulatory requirements and gaps, with periodic reassessment as development progresses and scientific rationale for the studies to be conducted and data generated.  
  • Coordinated scientific and dossier preparation, ensuring consistency across CMC, clinical, labelling and nonclinical documentation.  
  • Structured submission planning and quality controls, aligned with application-specific and regional requirements.  
  • Proactive review-response preparedness, supported by clear responsibilities, accessible evidence and cross-functional collaboration.  

Together, these practices provide a stronger foundation for managing Regulatory complexity and maintaining continuity across the development and submission lifecycle.  

A more predictable path begins with connected expertise  

Regulatory approval will always involve scientific assessment, evolving requirements, and decisions that remain within regulators' authority. What biopharmaceutical companies can influence is the quality of their preparation, the clarity of their Regulatory decisions and the effectiveness of coordination across the submission lifecycle.  

At Freyr Solutions, our approach to Regulatory support brings together Regulatory Strategic guidance, submission roadmaps, Gap assessment of generated data, dossier preparation, submission management, and Health Authority Review Support.  

By connecting expertise across Regulatory Affairs CMC, Medical Writing, labelling, Pharmacovigilance and Publishing & Submissions, we help sponsors evaluate Regulatory pathways, prepare scientifically built dossiers, manage submission requirements and respond to questions throughout the review and approval process. Ultimately, a more predictable path to approval is built through a series of informed, connected Regulatory decisions, supported by scientific readiness and coordinated execution at every stage.  

For organisations preparing an upcoming submission or planning a broader global Regulatory programme, the opportunity lies in evaluating these decisions collectively and building readiness into the process from the beginning.  

Planning your next Regulatory submission?  

Connect with Freyr's Regulatory experts to explore how integrated Regulatory planning, dossier readiness and submission support can help your team prepare for the next milestone.  

Explore Freyr's Regulatory Capabilities